Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Novartis Pharma AG, Basel, Switzerland.
Cephalalgia. 2020 Oct;40(11):1212-1223. doi: 10.1177/0333102420937655. Epub 2020 Jun 27.
In recent years, vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptides (PACAPs) have gained special interest in headache science. VIP and PACAPs (two isoforms, PACAP27 and PACAP38) are related in structure and function, as are their receptors, but they show differences in vasodilating- and headache-inducing properties. Intravenous infusion of PACAP27 or PACAP38, but not VIP, induces a long-lasting dilation of cranial arteries and delayed headache. The relationship between the long-lasting cranial vasodilation and headache development is not fully clarified.
In a double-blinded, placebo-controlled, crossover study in 12 healthy volunteers, diameter changes of cranial arteries, occurrence of headache and the parasympathetic system were examined before, during and after a 2-hour continuous intravenous infusion of VIP and placebo. Primary endpoints were the differences in area under the curve for the superficial temporal artery diameter and headache intensity scores, as well as in headache incidence, between VIP and placebo.
The superficial temporal artery diameter was significantly larger on the VIP day compared to placebo ( < 0.001) and the dilation lasted for more than 2 h. The incidence of headache was higher ( = 0.003) on the VIP day compared to the placebo day. The difference in headache intensity scores was more evident in the post-infusion period (120-200 min, = 0.034) and in the post-hospital phase (4-12 h, = 0.025). Cranial parasympathetic activity, measured through the production of tears, was higher during VIP compared to placebo ( = 0.033).
Continuous intravenous infusion of VIP over 2 h induced a long-lasting cranial vasodilation, activation of the cranial parasympathetic system, and delayed mild headaches in healthy volunteers. The study is registered at ClinicalTrials.gov (NCT03989817).
近年来,血管活性肠肽(VIP)和垂体腺苷酸环化酶激活肽(PACAPs)在头痛科学中引起了特别关注。VIP 和 PACAPs(两种同工型,PACAP27 和 PACAP38)在结构和功能上相关,它们的受体也是如此,但它们在血管扩张和引起头痛的特性上存在差异。静脉内输注 PACAP27 或 PACAP38 而不是 VIP 会导致颅动脉长时间扩张和延迟性头痛。颅动脉长时间扩张与头痛发展之间的关系尚未完全阐明。
在 12 名健康志愿者的双盲、安慰剂对照、交叉研究中,在 2 小时持续静脉输注 VIP 和安慰剂之前、期间和之后,检查颅动脉直径变化、头痛发生和副交感神经系统。主要终点是 VIP 和安慰剂之间的颞浅动脉直径和头痛强度评分的曲线下面积差异,以及头痛发生率的差异。
与安慰剂相比,颞浅动脉直径在 VIP 日显著增大( < 0.001),并且扩张持续超过 2 小时。VIP 日头痛的发生率高于安慰剂日( = 0.003)。头痛强度评分的差异在输注后期间(120-200 分钟, = 0.034)和住院后期间(4-12 小时, = 0.025)更为明显。通过产生眼泪来测量的颅副交感神经活动在 VIP 期间高于安慰剂( = 0.033)。
在健康志愿者中,2 小时静脉内输注 VIP 会引起长时间的颅动脉扩张、颅副交感神经系统激活和延迟性轻度头痛。该研究在 ClinicalTrials.gov 注册(NCT03989817)。